Chinese neurosurgical consensus updates prolactinoma diagnosis and treatment

A multidisciplinary Chinese panel has issued updated evidence-based guidance for diagnosing and treating prolactinomas, the most common functional pituitary tumors. The June 2026 consensus aims to improve earlier detection, standardize care and guide more personalized treatment across hospitals and specialties.

Why it matters: - Prolactinomas account for nearly half of all hormone-secreting pituitary adenomas and can affect fertility, sexual function, vision and quality of life. - Earlier recognition and more standardized care may reduce complications, especially in women of reproductive age, men, children and adolescents. - The updated guidance aims to help clinicians make faster diagnoses, choose safer treatments and preserve endocrine and reproductive function.

What happened: - A multidisciplinary panel in China developed an updated evidence-based consensus on prolactinoma diagnosis and treatment. - The study was published online in Volume 12 of Chinese Neurosurgical Journal on June 8, 2026. - The original paper is titled Chinese consensus on the diagnosis and treatment of prolactinomas (2025 edition). - The paper includes contributions from experts in endocrinology, neurosurgery and evidence-based medicine, along with the China Pituitary Adenoma Specialist Council.

The details: - The consensus process included 60 specialists from neurosurgery, endocrinology, obstetrics and gynecology, neuroradiology, radiation oncology and evidence-based medicine. - The panel used internationally recognized guideline frameworks and the GRADE approach. - The final document includes 36 recommendations covering screening, assessment, diagnosis, treatment and long-term monitoring. - Serum prolactin testing is recommended for patients with suggestive symptoms. - Clinicians should rule out physiological, pharmacological and other pathological causes of hyperprolactinemia before diagnosing prolactinoma. - The guidance highlights special diagnostic issues such as macroprolactinemia, the Hook effect, hereditary syndromes and high-risk patients who may benefit from genetic testing. - Pituitary magnetic resonance imaging remains the preferred diagnostic tool. - Dynamic contrast-enhanced MRI may improve detection of small tumors. - The guidance gives practical advice on imaging follow-up. - Some patients may need vascular imaging to detect associated intracranial aneurysms before surgery. - The consensus recommends individualized management for pregnant women, male patients and refractory cases.

Between the lines: - The new guidance reflects how advances in surgery, imaging and drug therapy have changed prolactinoma care over the past decade. - The emphasis on multidisciplinary care suggests prolactinomas are increasingly being managed as a shared endocrinology-neurosurgery problem rather than a single-specialty issue. - Standardized recommendations could also make future research easier for difficult areas such as drug resistance, pregnancy-associated prolactinomas and hereditary disease. - Prof. Li said the consensus provides insight into epidemiology, clinical features, diagnosis and treatment strategies. - Prof. Zhu said the consensus balances clinical needs with international evidence-based standards and offers a reliable reference for diagnosis and treatment.

What's next: - Broader adoption could improve consistency in patient management across hospitals and healthcare settings. - Earlier diagnosis and better treatment selection may help preserve fertility and endocrine function. - Longer term, evidence-based multidisciplinary care could improve quality of life and outcomes for patients with prolactinomas. - The work was supported by the Key Program of the National Natural Science Foundation of China under grants 82541022 and 82573142.

The bottom line: - China’s updated prolactinoma consensus turns newer evidence into practical guidance designed to improve diagnosis, personalize treatment and reduce long-term harm.